Picture EBD Group BioPharm America 2020 Digital Event BEU2020 650x81
Collaboration › Details

Seres Therapeutics–Oppenheimer: investor conference, 201903 supply service Seres presents at Oppenheimer Annual Healthcare Conference in NYC


Period Period 2019-03-19
Region Region New York, NY
  Country United States (USA)
Organisations Partner, 1st Seres Therapeutics Inc. (Nasdaq: MCRB)
  Partner, 2nd Oppenheimer & Co. Inc.
  Group Oppenheimer (Group)
Products Product Oppenheimer & Co. Annual Healthcare Conference 2019 New York
  Product 2 microbiomic treatment (live biotherapeutic product, LBP)
Person Person Tanzi, Carlo (Seres Therapeutics 201903 VP IR + Corporate Communications)

Seres Therapeutics, Inc.. (3/5/19). "Press Release: Seres Therapeutics to Present at Three Upcoming March Conferences". Cambridge, MA.

Seres Therapeutics, Inc. (Nasdaq: MCRB) today announced that it will present at each of the following upcoming healthcare conferences:

> Chardan’s Inaugural Microbiome Summit: a corporate overview will be presented on Thursday, March 7th at 8:10 a.m. ET in New York, NY.

> Cowen and Company 39th Annual Health Care Conference: a corporate overview will be presented on Monday, March 11th at 11:20 a.m. ET in Boston, MA.

> Oppenheimer 29th Annual Healthcare Conference: a corporate overview will be presented on Tuesday, March 19th at 11:30 a.m. ET in New York, NY.

A live audio webcast of each presentation will be available under the “Investors and Media” section of Seres’ website. A replay will become available approximately one hour after each event and will be archived for 21 days.

About Seres Therapeutics

Seres Therapeutics, Inc. (Nasdaq: MCRB) is a leading microbiome therapeutics platform company developing a novel class of biological drugs that are designed to treat disease by restoring the function of a dysbiotic microbiome, where the state of bacterial diversity and function is imbalanced. Seres’ most advanced program, SER-109, has obtained Breakthrough Therapy and Orphan Drug designations from the U.S. Food and Drug Administration and is in Phase 3 development for recurrent C. difficile infection. SER-287 is being evaluated in a Phase 2b study in patients with active mild-to-moderate ulcerative colitis. Seres is developing SER-401 in a Phase 1b study in metastatic melanoma to augment the efficacy of anti-PD-1 immunotherapy. For more information, please visit

IR or PR Contact:
Carlo Tanzi, Ph.D., Seres Therapeutics, 617-203-3467
Vice President, Investor Relations and Corporate Communications

Record changed: 2019-03-17


Picture [iito] Männer Ballett 650x80px

More documents for Seres Therapeutics Inc. (Nasdaq: MCRB)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture ConsulTech GmbH Berlin Grant Application and Coordination 650x80px

» top